Hepatitis C future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 32: | Line 32: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:FinalQCRequired]] | |||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Hepatology]] | |||
Latest revision as of 22:05, 29 July 2020
|
Hepatitis C |
|
Diagnosis |
|
Treatment |
|
Hepatitis C future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatitis C future or investigational therapies |
|
Risk calculators and risk factors for Hepatitis C future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor-In-Chief: Nina Axiotakis [2]
Overview
Several investigational drugs are being tested for use in hepatitis C such as danoprevir, asunaprevir, vaniprevir, and ledipasvir among others.
Future Or Investigational Therapies
Several investigational drugs are being tested for use in hepatitis C. These agents focus on proteins essential for viral replication. The table below summarizes the agents currently being investigated.
| Name | Alternative | Mechanism of Action |
| Danoprevir[1] | RG7227/ITMN-191 | Inhibitor of the HCV NS3/4A serine protease |
| Asunaprevir[2] | BMS-650032 | Inhibitor of the HCV NS3/4A serine protease |
| Vaniprevir[3] | MK-7009 | Inhibitor of the HCV NS3/4A serine protease |
| Daclatasvir[4] | BMS-790052 | Inhibitor of the HCV non-structural protein NS5A |
| Mericitabine[5] | RG7128 | Inhibitor of the HCV NS5B polymerase |
| Ledipasvir[6] | GS-5885 | Inhibitor of the HCV non-structural protein NS5A |
| Faldaprevir[7] | BI-2010335 | Protease inhibitor |
References
- ↑ Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S; et al. (2014). "Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease". J Med Chem. 57 (5): 1753–69. doi:10.1021/jm400164c. PMID 23672640.
- ↑ Eley T, He B, Chang I, Colston E, Child M, Bedford W; et al. (2014). "The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor". Antivir Ther. doi:10.3851/IMP2773. PMID 24704773.
- ↑ Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S; et al. (2013). "A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment". J Hepatol. 59 (1): 11–7. doi:10.1016/j.jhep.2013.02.008. PMID 23439259.
- ↑ Herbst DA, Reddy KR (2013). "NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection". Expert Opin Investig Drugs. 22 (10): 1337–46. doi:10.1517/13543784.2013.826189. PMID 23931586.
- ↑ Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C; et al. (2013). "JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients". Hepatology. 58 (2): 514–23. doi:10.1002/hep.26275. PMID 23359491.
- ↑ Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E; et al. (2014). "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis". N Engl J Med. 370 (20): 1879–88. doi:10.1056/NEJMoa1402355. PMID 24720702.
- ↑ Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W; et al. (2014). "Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection". Liver Int. 34 (1): 78–88. doi:10.1111/liv.12254. PMID 23944720.